Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Atherosclerosis|June 30, 2019
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trialsKausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, et al.
European Journal of Preventive Cardiology|February 25, 2020
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumabAntonio J Vallejo-Vaz, Lawrence A Leiter, Stefano Del Prato, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 21, 2018
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 StudiesHenry N Ginsberg, Michel Farnier, Jennifer G Robinson, et al.
Cardiovascular Diabetology|November 11, 2019
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studiesKausik K Ray, Stefano Del Prato, Dirk Müller-Wieland, et al.
Diabetes, Obesity & Metabolism|September 15, 2017
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trialLawrence A Leiter, Bertrand Cariou, Dirk Müller-Wieland, et al.
Diabetes, Obesity & Metabolism|February 14, 2018
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trialKausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Cardiovascular Diabetology|May 27, 2017
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular riskDirk Müller-Wieland, Lawrence A Leiter, Bertrand Cariou, et al.
European Heart Journal|March 7, 2023
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trialGregory G Schwartz, Michael Szarek, Deepak L Bhatt, et al.
Pageof 2